This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
For TALZENNA® (talazoparib) Prescribing Information click here.
.
TALZENNA® is indicated in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.1
.
TALZENNA® + enzalutamide: The first and only PARPi + ARPi combination to offer a statistically significant increase in median rPFS and OS in first-line treatment for mCRPC with or without HRR gene alterations vs. enzalutamide + placebo.2, 3
This video highlights the combination of talazoparib, a PARP inhibitor, with enzalutamide, an androgen receptor inhibitor, which enhances treatment efficacy by preventing cancer cells from repairing their DNA, leading to cell death.
A guide to support optimal treatment outcomes for patients prescribed TALZENNA® + enzalutamide for the treatment of mCRPC, with or without HRR gene alterations.
Stay up to date with the latest relevant healthcare, medical and promotional information from Pfizer.
Abbreviations:
ARPi - Androgen Receptor Pathway Inhibitor, DNA - Deoxyribonucleic Acid, HRR - Homologous Recombination Repair, mCRPC - Metastatic Castration Resistant Prostate Cancer, MOA - Mechanism of Action, OS - Overall Survival, rPFS - Radiographic Progression-Free Survival
1. TALZENNA® (talazoparib) Summary of Product Characteristics for United Kingdom. Available on www.medicines.org.uk
2. Agarwal N, Azad AA, Carles J, et al. Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial. Oral Slides Presented at ASCO GU Annual Meeting, 2025
3. Agarwal N, Azad AA, Carles J, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 2023;402(10398):291-303. [Accessed: May 2025].
4. Fizazi K, Azad AA, Matsubara N, et al. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the
phase 3 TALAPRO-2 trial. Nat Med 2024;30(1):257-64. [Accessed: May 2025].
PP-TXT-GBR-0033 May 2025
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2026 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-13971. December 2025